🇺🇸 FDA
Patent

US 11230537

Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[2-oxopyridin-1-yl)methyl]phenyl} methyl)pyrazole-4-carboxamide as iallikrein inhibitors

granted A61PA61P1/04A61P1/18

Quick answer

US patent 11230537 (Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[2-oxopyridin-1-yl)methyl]phenyl} methyl)pyrazole-4-carboxamide as iallikrein inhibitors) held by KalVista Pharmaceuticals Limited expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
KalVista Pharmaceuticals Limited
Grant date
Tue Jan 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61P, A61P1/04, A61P1/18, A61P11/00, A61P13/12